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Abstract Five neurodegenerative diseases are caused by pro- 
teins with expanded polyglutamine domains. Toxicity of these 
proteins has been previously identified only in mammals, and no 
simple model systems are available. In this paper, we demon- 
strate in E. coli that long polyglutamine domains (59-N 
residues) as GST-fusion proteins inhibit growth while smaller 
glutamine (10-35 residues) or polyalanine (61 residues) domains 
have no effect. Analogously in humans, polyglutamine repeats 
less than 3540 glutamines produce a normal phenotype, while 
expansion greater than 40 glutamines is always associated with 
disease. Expression of polyglutamine proteins in E. coli may help 
identify the molecular mechanism of pathogenesis of CAG 
trinucleotide repeat diseases and be a useful screen to identify 
potential therapeutic compounds. 
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1. Introduction 
Five neurodegenerative diseases are caused by expanded 
CAG repeats which encode expanded polyglutamine domains 
in the expressed disease proteins [l-6]. These dominantly in- 
herited diseases, Huntington’s disease, dentatorubral pallido- 
luysian atrophy (DRPLA), spinocerebellar ataxia I (SCAl), 
spinobulbar muscular atrophy (SBMA) and Machado-Joseph 
disease (MJD) result from gain-of-function mutations [7,8]. 
The expanded polyglutamine domain itself is likely to be di- 
rectly involved in disease pathogenesis since: (a) all five pro- 
teins are associated with neurodegenerative diseases with sim- 
ilar phenotype, yet the polyglutamine domain is the only 
region of homology in the expressed proteins [8]; (b) polyglu- 
tamine repeats less than 3540 glutamines produce a normal 
phenotype, while expansion greater than 40 glutamines is al- 
ways associated with disease [9]; (c) the size of the polygluta- 
mine repeat is the major determinant of age-of-onset and 
clinical phenotype [3,6,10-121; and (d) expression of a portion 
of the Machado-Joseph protein containing an expanded poly- 
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glutamine repeat causes neuronal degeneration in transgenic 
mice and kills transfected COS cells [13]. 
The mechanism by which a polyglutamine domain results in 
disease pathogenesis is unknown. A potential mechanism of 
pathogenesis is abnormal protein-polyglutamine interactions 
[8,14]. To characterize further the interactions between poly- 
glutamine proteins and other proteins, and to obtain a source 
of polyglutamine domain peptides, we cloned CAG repeats of 
varying lengths into a GST-fusion protein vector and ex- 
pressed these proteins in E. coli. We unexpectedly observed 
that expression of GST-fusion proteins with 59 or greater 
glutamine residues killed E. coli, while GST-fusion proteins 
containing lo-35 glutamines did not. Expression of a GST- 
fusion protein containing 61 alanine residues was not toxic. 
Demonstration of length-dependent polyglutamine-induced 
toxicity in bacteria may simplify examination of the mecha- 
nism of pathogenesis and provide a system for screening po- 
tential therapeutic compounds. 
2. Materials and methods 
2.1. Construction of polyglutamine clones 
Polyglutamine repeat-GST fusion proteins were synthesized by 
PCR from the human DRPLA cDNA [15] with modification of co- 
dons to those frequently observed in E. coli. Each clone was named Q 
followed by the number of uninterrupted glutamines. A DRPLA 
cDNA containing 79 or 14 repeats was used ai a template to construct 
clones 081. 019 and 010 usine mimers 50: 5’-TGATG- 
GATCC&?K?CACCCATCACCATICA’CCAC and.3Q: 5’-TGAT- 
GAATTCCGGCGGACCAGAGTTACCGTGATG. For construc- 
tion of 462 and Q58, we used TA62 and TA55 plasmid DNA [3]. 
For construction of Q35, genomic DNA with 35/14 CAG repeats in 
the DRPLA gene was amplified using primers Smin: 5’-TGATG- 
GATCCTCTTTCCCTCCCCCAACAAG and 3min: 5’-TGAT- 
GAATTCCCCTTGAGAAGTGGAAGAGGAAG. The PCR prod- 
uct was then used as a template for further PCR using primers 5Q 
and 3Q. Clone Q(-) lacking the polynlutamine tract was constructed 
by PCR of the sequences adjacent t&but excluding, the CAG repeat 
usins mimers 5min and SO(-): 5’-GTGGTGATGGTGATGGGTG- 
GA&k, 3min and 3Q(-j; $-CATCACGGTAACTCTGGTCCG- 
CCTCCT. The PCR products were then ligated. PCR reaction con- 
ditions were as follows: 20 mM Tris-HCl, pH 8.75, 10 mM KCl, 10 
mM (NH&S04, 2 mM MgS04, 0.1% (v/v) Triton X-100, 0.1 mg/ml 
bovine serum albumin, 5% (v/v) DMSO, 200 bM dNTP, 10 pmol of 
primer and 2 units of Pfu DNA polymerase (Stratagene). After 3 min 
denaturation at 94”C, samples were subjected to 25 cycles of 30 s 
denaturation at 94”C, 30 s annealing at 55°C and 45 s extension at 
72°C and a final extension at 72°C for 6 min. Fragments were cloned 
into the BamHI and EcoRI site of the pGEX-4T-3 vector which con- 
tains an IPTG inducible promoter (Pharmacia). The recombinant 
DNAs were transformed into TOP 10F’ cells (Invitrogen). The nu- 
cleotide sequences of all constructs were confirmed by the dideoxynu- 
cleotide chain terminator method. The number of each clone reflects 
the number of glutamines in the polyglutamine domain. The sequence 
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of polyglutamine stretch of each clone was as follows: 
QlO : (CAGCAA),(CAG), 
Q19 : (CAGCAA)2(CAG),, 
Q35 : (CAGCAA)2(CAG)B, 
Q59 : (CAGCAA),(CAG),, 
Q62 : (CAGCAA)?(CAG),s 
Q81: (CAGCAA),(CAG),,CAACAGCAA(CAG),, 
2.2. Construction of polyalanine clones 
The polyalanineIdST fusion protein was synthesized by amplifying 
the 462 plasmid DNA using 5’-TGATGGATCCTTCCACC- 
CATCCCCATCCCCACCAGCAGCAGCAGCA and 34 as primers. 
To eliminate the effect of C-terminal differences in the fusion proteins 
produced by the polyalanine and polyglutamine plasmids, we ampli- 
fied the 062 alasmid DNA using 50 and 5’-TGATGAA’ITCC- 
GGCGGiCCiGAGTTTCAGCGACT?TGCTG as primers. PCR 
and cloning were performed as described above. The nucleotide se- 
quences of all constructs were confirmed by the dideoxynucleotide 
chain terminator method. Clone A61-SR contained 61 alanines, and 
the clone Q62-SR contained 62 glutamines. The carboxyl-terminus of 
the fusion proteins was identical, serine and arginine. 
Summary of clones: 
Q(-) : GST - LVPRGSVSTHHHHHHHGNSGPPEFPGRLERPHRD 
QlO to Q81 : GST - LVPRGSVSTHHHHH(Q)10_81HHGNSGPPEF- 
PGRLERPHRD 
Q62 - SR : GST - LVPRGSVSTHHHHH(Q),,SR 
A61 - SR : GST - LVPRGSFHPSPSPP(A),,SR 
2.3. Culture conditions 
Individual clones of TOPlOF’ (Invitrogen) or BL21(DE3)pLysS 
(Novagene) cells containing the indicated plasmid were grown over- 
night at 30°C in LB medium in the presence of 100 pg/ml ampicillin 
and 34 pg/ml chloramphenicol in the case of pLysS cells. The cells 
were diluted to an ODsoo of 0.1 in LB medium supplemented with 
antibiotics. After 30 min incubation at 37”C, either 0.1 or 1 mM 
IPTG was added to each culture. At the indicated times, a 200 ~1 
aliquot of each culture was removed. Cell growth was monitored for 
up to 5 h by measuring cell densities by 0D.s~ on a Beckman DU-64 
spectrophotometer. 
Colony forming ability was assayed 1 and 3 h after adding 0.1 mM 
IPTG. Aliquots of cell culture were removed, diluted, and plated on 
LB plated containing ampicillin. After overnight incubation, viable 
colonies were counted and expressed as colony forming units 
(CFU)/pl of culture. 
2.4. Protein analysis 
100 ~1 of cell culture was centrifuged and the cell pellet collected. 
The cell pellet was suspended in Laemmli buffer containing SDS and 
2-mercaptoethanol and boiled for 3 min. The samples were electro- 
phoresed on a 10% polyacrylamide gel containing 2% SDS. Proteins 
were transferred to Immobilon P membrane (Millipore) by standard 
Western transfer techniques. After transfer, the membrane was incu- 
bated in blotto (5% dried milk in Tris-buffered saline (pH 7.6) with 
0.1% Tween 20 (Pierce)) at room temperature for 1 h. The membrane 
was incubated with goat polyclonal anti-GST antibody (Pharmacia) at 
1: 10 000 dilution in blotto overnight at 4”C, then washed five times in 
blotto. The membrane was exposed to rabbit anti-goat secondary 
antibody conjugated with horseradish peroxidase (1:2000 dilution) 
for 1 h at room temperature, then washed seven times in blotto. 
Horseradish peroxidase was visualized with an enhanced chemilumi- 
nescence detection kit (Amersham) and exposed to Hyperfilm ECL 
(Amersham). 
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3. Results 
3.1. Expression of glutamine-GST fusion proteins in E. coli 
Expression of GST-fusion proteins with 10-81 glutamines 
in E. coli is shown in Fig. 1. Isopropylthio-P-o-galactoside 
(IPTG) induction increased expression of GST-fusion proteins 
containing lo-35 glutamines. Unexpectedly, identical treat- 
ment of bacteria transfected with plasmids containing 81 glu- 
tamines decreased GST-fusion protein expression. Polygluta- 
mine-containing proteins migrate on polyacrylamide gels 
slightly slower than predicted from molecular mass; aberrant 
migration of these proteins on SDS-polyacrylamide gels has 
been reported [ 16,171. 
To determine whether the induction of GST fusion proteins 
containing a polyglutamine domain was toxic to bacteria we 
assayed cell growth. Prior to addition of IPTG, the growth 
rate of E. coli containing plasmids encoding GST-fusion pro- 
teins with lo-81 polyglutamines was equivalent to the growth 
rate of E. coli transformed with the Q(-) construct lacking a 
polyglutamine domain (Fig. 2A). The flanking peptides en- 
coded in these plasmids were identical. After induction with 
IPTG, the growth rate of E. colt’ expressing GST-fusion pro- 
teins greater than 59 glutamines was markedly reduced com- 
pared to E. coli expressing GST-fusion proteins with smaller 
glutamine domains (0.1 mM IPTG, Fig. 2B; 1.0 mM IPTG, 
Fig. 2C). In addition, the toxicity of polyglutamine domain 
proteins increased quantitatively with the size of the expan- 
sion when the repeat contained more than 59 glutamines (Fig. 
2). Fig. 2 also demonstrates that increasing the concentration 
of IPTG increases toxicity. 
The inhibition in growth rate shown in Fig. 2 could be 
caused by slowing of growth or by cell death. To address 
this question, we assayed E. coli survival by colony forming 
ability. Between 1 and 3 h after induction with 0.1 mM IPTG, 
E. coli transformed with QlO-GST showed a 500% increase in 
colony forming units. In contrast, under identical conditions, 
E. coli transformed with Q62-GST had a 75% reduction in 
colony forming units. Growth inhibition, therefore, was due 
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Fig. 1. Expression of GST-polyglutamine fusion proteins. E. coli 
transformed with plasmids encoding GST-fusion proteins QlO (lanes 
1,2); Q35 (lanes 3,4); Q59 (lanes 5,6) and QSl (lanes 7,8) were 
grown in the absence (odd lanes) or presence (even lanes) of 1.0 
mM IPTG. 
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Fig. 2. Viability of E. coli expressing GST-polyglutamine fusion 
proteins. E. coli transformed with clones Q(-) (+); QlO (m); Q19 
(A); Q35 (0); Q59 (A); 462 (0); or QSl (0) were incubated in 
the absence (A) or uresence of 0.1 mM IPTG (B) or 1.0 mM IPTG 
(C). . ’ L 
to inability of bacteria to replicate. Inability of bacteria to 
replicate and form colonies is synonymous with cell death. 
Toxicity is not due to selective loss of longer polyglutamine 
plasmids [l&19] since cell growth is inhibited with induction 
of the polyglutamine fusion protein in either the presence or 
absence of ampicillin. Length-dependent toxicity of polyglu- 
tamine-GST fusion proteins was also observed in another 
strain of E. coli (BL21(DE3)pLysS). Toxicity is not due to 
depletion of glutamine, since supplementation of the media 
with glutamine (up to 100 mM) did not effect toxicity. 
3.2. Expression of polyalanine-GST fusion protein 
To determine whether the toxicity of these proteins is spe- 
cific for polyglutamine or occurs with any homopolymer of 
equivalent length, we constructed a polyalanine-GST fusion 
protein containing 61 alanines. Alanine translation results 
from shifting the reading frame of the plasmid from CAG 
to GCA. To minimize variability at the carboxy-terminus 
the sequence following the repeat was truncated. Plasmids 
were constructed which produce either 62 glutamine residues 
(clone Q62-SR) or 61 alanine residues (clone A61-SR) with 
serine and arginine at the carboxy-terminus. E. coli trans- 
formed with Q62-SR or A61-SR produced GST-fusion pro- 
teins migrating on polyacrylamide gels as shown in Fig. 3. 
IPTG increased expression of both GST-Q6ZSR and the 
GST-polyalanine fusion protein (A61-SR), but the effects on 
bacterial growth of the two constructs differed. Prior to in- 
137 
cubation with IPTG, E. coli transformed with Q62-SR or 
A61-SR grew at the same rate (Fig. 4A). After induction by 
IPTG, E. coli expressing the A61-SR continued growing, 
while growth of bacteria expressing Q62-SR was inhibited 
(Fig. 4B). The growth curve of A61-SR was identical to the 
Q( -)-GST construct. 
4. Discussion 
Although proteins containing expanded polyglutamine do- 
mains are expressed in virtually every tissue, they appear to 
cause cell death only in the central nervous system [16,17] and 
in a transiently transfected mammalian cell line [13]. In this 
paper we demonstrate that expression of long polyglutamine 
repeats (59-81 residues) in GST-fusion proteins causes length- 
and concentration-dependent inhibition of cell growth in E. 
coli. In contrast, expression of smaller glutamine repeat pep- 
tides (10-35 residues) has no adverse effect on bacterial cell 
growth. This toxicity is not indiscriminate since expression of 
an equivalent length polyalanine-GST fusion protein has no 
effect on bacterial growth. The inhibition of growth is not 
simply a change in the rate of growth. The colony forming 
unit assay demonstrates that E. coli expressing long polyglu- 
tamine repeats are unable to replicate. It is also unlikely that 
toxicity is due to glutamine depletion because supplementa- 
tion of the media with glutamine had no effect. Similarly, 
glutamyl t-RNA depletion is unlikely because large amounts 
of Q35-GST protein can be made with no effect on growth. 
Numerous recombinant proteins are toxic in E. coli (rat 
insulin [20]; HIV protease [21]; Streptococcus pneumoniae 
ma1 and ami loci [22]; cytochrome cp [23] and mutations in 
tRNA synthetase [24]). These proteins are hypothesized to 
cause toxicity by (a) impairing export machinery for secreted 
proteins [22], (b) by the overexpression of secreted proteins 
[20,22], (c) by proteolysis [21] and (d) by depletion of tRNA 
[24]. The mechanism of polyglutamine-mediated cell death is 
unknown and the polyglutamine constructs produce intracel- 
lular proteins with no known enzymatic function. The GST 
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Fig. 3. Expression of GST-polyglutamine or GST-polyalanine fusion 
proteins. E. coli transformed with plasmids encoding GST-fusion 
proteins A61-SR (lanes 1,2); Q62-SR (lanes 3,4) or 462 (lanes 5,6) 
were grown in the absence (odd lanes) or presence (even lanes) of 
1.0 mM IPTG. 
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Fig. 4. Viability of E. coli expressing GST-polyglutamine or GST- 
polyalanine fusion proteins. E. coli transformed with clones A61-SR 
(*) or Q62-SR (0) were incubated in the absence (A) or presence 
of 1.0 mM IPTG (B). Bacterial number was assayed by measuring 
ODsoo at the times indicated. OD so0 for E. cob transformed with 
Q(-) (+) at the 300 min time point is also shown in (B). 
domain of the fusion protein alone, or associated with poly- 
glutamine domains up to 35 glutamines or 61 alanines, has no 
effects on survival. 
In humans the size of the polyglutamine repeat determines 
whether disease occurs. The size of the polyglutamine domain 
which causes bacterial toxicity (greater than 35 glutamines) is 
also the size causing human disease (approx. 40 or more glu- 
tamines) [9]. In addition, toxicity of the polyglutamine fusion 
proteins in E. coli increases with length, analogous to the 
effect of repeat size on age-of-onset and disease severity in 
humans [3,6,10-121. Length-dependent toxicity in the nervous 
system and bacteria may be caused by these large polygluta- 
mine domains adopting a novel conformation. A unique 
structure for polyglutamine domains greater than 40 residues 
in length has been suggested by Trottier et al. who isolated a 
monoclonal antibody which specifically identifies proteins 
containing enlarged polyglutamine repeats [25]. 
Another factor contributing to toxicity is the quantity of 
GST-polyglutamine protein. The extent of toxicity is a direct 
function of the concentration of the inducer IPTG. Prior to 
induction with IPTG, the growth of E. coli producing an 81 
repeat polyglutamine protein was identical to E. coli produc- 
ing smaller polyglutamine repeat proteins despite ‘leaky’ pro- 
duction of a small amount of protein. Increased concentra- 
tions of IPTG caused greater inhibition of E. coli growth. A 
similar effect of protein expression was found in transgenic 
mouse models of SBMA and SCAl [26,27]. In a model of 
SBMA, low level expression of an androgen receptor contain- 
ing an expanded repeat did not cause clinical or pathologic 
signs of disease [26]. A transgenic model of SCAl demon- 
strated the disease phenotype only in mice with a high level 
of expression of the ataxin 1 transgene [27]. 
The mechanism by which expanded polyglutamine domain 
proteins cause toxicity in bacteria, transfected fibroblasts or in 
the nervous system is not known. Abnormal energy metabo- 
lism has been proposed in the pathogenesis of HD [28]. 
Chronic, systemic administration of the TCA cycle inhibitor 
3-nitropropionic acid (3-NP) in primates, for example, pro- 
duces a disease phenotype clinically and pathologically similar 
to HD [29]. 3-NP inhibits succinate dehydrogenase, a meta- 
bolic enzyme present in all cells, yet pathology is restricted to 
a subset of neurons in the central nervous system. Analo- 
gously, the polyglutamine repeat proteins are widely expressed 
throughout the body, yet pathology is restricted to certain 
neuronal populations. The pathology of the polyglutamine 
repeat diseases may be restricted to the nervous system be- 
cause neurons are long-lived, post-mitotic cells with high en- 
ergy requirements. Cell death may occur in other tissues, but 
the low death rate allows replacement by mitosis. Alterna- 
tively, neuron-specific target proteins may mediate degenera- 
tion. The latter possibility seems less likely in view of the 
toxicity of polyglutamine in COS cells [13] and in E. coli. 
A potential mechanism of toxicity is a quantitative or qua- 
litative change in protein-polyglutamine domain interactions 
which vary as a function of polyglutamine length [30]. Poly- 
glutamine domains can mediate protein-protein interactions 
by forming polar zippers. Perutz has demonstrated that poly- 
glutamine peptides form hydrogen bonded P-pleated sheets, 
but little is known about the stability of these interactions 
as a function of chain length [14,31]. Our observation that 
polyalanine is not toxic in E. coli suggests that structural 
motifs may be critical in toxicity because polyalanine tends 
to form alpha helices rather than P-pleated sheets [32]. 
RNA-protein interactions have recently been demonstrated 
between CAG repeat RNA and RNA binding proteins [33], 
but our data suggest that this is an unlikely cause of toxicity 
in E. coli. The polyalanine construct A61-SR contains a long 
CAG repeat, but it is frame-shifted to GCA so that it is 
translated as alanine instead of glutamine. If pathogenesis 
were mediated by RNA-protein interactions, A61-SR would 
have equal toxicity with Q61-SR because of the equal number 
of CAG repeats in their RNA, but Q61-SR inhibits growth 
while A61-SR has no effect. A similar absence of toxicity 
despite RNA expression has also been reported in a transgenic 
mouse with a frame-shift in the huntington gene [34]. 
As shown here, expanded polyglutamine domain proteins 
are toxic in prokaryotic cells. The polyglutamine toxicity in 
bacteria mimics eukaryotic systems in its length and concen- 
tration dependence. E. coli expressing expanded polygluta- 
mine proteins may prove to be a useful model system to 
identify other molecules which interact with polyglutamine 
proteins, to characterize protein interactions, and to screen 
for therapeutic compounds. 
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